Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2011	Dec. 31, 2010
Assets
Cash and cash equivalents	$ 492,508	$ 478,668
Grant receivable	0	244,479
Debt issue costs	0	4,408
Other current assets	116,826	141,622
Total current assets	609,334	869,177
In-process research and development	17,742,110	17,742,110
Property and equipment, net	1,816	2,984
Other assets	7,750	21,370
Total assets	18,361,010	18,635,641
Liabilities and Stockholders' Deficiency
Notes payable, current portion, net of discount	775,290	2,054,246
Accounts payable and accrued expenses	207,649	223,516
Interest payable, current portion, net of beneficial conversion	160,061	480,890
Derivative liability	2,639,728	534,846
Total current liabilities	3,782,728	3,293,498
Notes payable, noncurrent portion, net of discount	16,475,433	16,130,571
Interest payable, noncurrent portion	252,396	626,697
Exchange obligation	0	3,949,176
Total liabilities	20,510,557	23,999,942
Commitments and contingencies
Stockholders' deficiency:
Preferred stock, $.001 par value. Authorized 1,500,000 shares; no shares issued and outstanding at June 30, 2011 and December 31, 2010	0	0
Common stock, value issued	2,596	2,419
Additional paid-in capital	58,291,913	55,927,180
Deficit accumulated during the development stage	(60,459,946)	(61,309,790)
Total stockholders' deficiency	(2,149,547)	(5,364,301)
Total liabilities and stockholders' deficiency	18,361,010	18,635,641
Contingently Issuable Share
Stockholders' deficiency:
Common stock, value issued	$ 15,890	$ 15,890